Poludan - instructions for use, dose, side effects, contraindications

Active substancePolyadenyl acid + Polyuridylic acidPolyadenyl acid + Polyuridylic acid

Similar drugsTo uncover

drops nazal.

Dosage form: & nbspnasal drops

Composition:

1 ml of the preparation contains:

active substance: polyriboadenyl acid potassium salt (potassium polyriboadenylate) 0.05 mg, polyribouridic acid potassium salt (potassium polyribouridilate) 0.0535 mg;

Excipients: sodium hydrophosphate (sodium phosphate 2-substituted) 2.0 mg, potassium dihydrogen phosphate (potassium phosphate 1-substituted anhydrous) 0.408 mg, disodium edetate (trilon B) 0.336 mg, sodium chloride 8.5 mg, water for injection up to 1 ml.

Description:Transparent colorless liquid.

Pharmacotherapeutic group:immunostimulating agent

ATX: & nbsp

S.01.A.D Antiviral drugs

Pharmacodynamics:

Poludan® is a biosynthetic polyribonucleotide complex of polyriboadenyl and polyribouridyl acids. Inductor synthesis of endogenous interferon. It stimulates the formation of mainly alpha-interferon, to a lesser extent beta and gamma-interferon. It induces the synthesis of interferon in peripheral blood leukocytes, as well as in tissues and organs containing lymphoid elements. A high level of interferon is maintained by daily administrations throughout the course.

Has a direct antiviral effect against influenza viruses and other acute respiratory viral infections. Modulates the cytokine response when the cells are infected with a virus.

Indications:

Treatment of influenza and other acute respiratory viral infections.

Contraindications:

Hypersensitivity to the components of the drug.

Dosing and Administration:

Locally.

For treatment of influenza and other acute respiratory viral infections in adults 2 drops in each nostril 5 times a day for 5 days in the acute phase of the disease - no later than 24-48 hours after the onset of symptoms.

Side effects:

Allergic reactions are rare.

Interaction:

With the simultaneous use of the drug Poludan® with enzyme preparations in communication from destroying action of enzymes on endogenous interferon, the clinical efficacy of the drug Poludan® is reduced.

Compatible with antibiotics and medicines for the treatment of viral infections.

Special instructions:

Adverse events are transient in nature and disappear after discontinuation of the drug after 1-3 days.

Form release / dosage:Nasal drops, 50 U / ml.

Packaging:

5 ml in glass bottles.

For 1 bottle complete with 1 lid-dropper along with instructions for use in a pack of cardboard.

By 3 bottles complete with 3 lids-droppers together with instructions for use in a pack with partitions or special cardboard sockets.

100 bottles complete with 100 dropper caps with an equal number of instructions for use in a cardboard box (for hospitals).

Storage conditions:

At a temperature of no higher than 30 ° C.

Keep out of the reach of children.

Shelf life:

2 gOh yeah.

Do not use after the expiration date.

Terms of leave from pharmacies:Without recipe

Registration number:LP-000155

Date of registration:13.01.2011

The owner of the registration certificate:LENS-PHARM, LLC LENS-PHARM, LLC Russia

Manufacturer: & nbsp

LENS-PHARM, LLC Russia

Information update date: & nbsp20.08.2015

Illustrated instructions

Instructions

Poludan® (Poludanum®)